Abstract
During recent years, many studies have stressed the importance of new approaches in the use of biological response modifiers (BRMs) in the treatment of cancer and infectious diseases. Although there is general agreement on the therapeutical potential of these agents, their clinical use did not yield the expected results. As a consequence, in the attempt to improve the efficacy of these molecules, many groups are trying different approaches, including combination therapies with various cytokines. In particular, it seems likely that combinations of different BRMs can result in a more potent effect than single treatments (1–4) The rationale of this new approach stems from the observations that immune physiologic responses involve cascades and feedback networks in which the release of one cytokine modulate both cytokine and cytokine-receptor production. Moreover, combination of BRMs could affect different immune effector cells.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Brunda MJ, Bellantoni D, Sulich V. In vivo anti-tumor activity of combinations of interferon a and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int. J Cancer 1987; 40: 365–71.
Ciolli V, Gabriele L, Sestili P, et al. Host antitumor mechanism in the combined IL-1/IL-2 therapy in mice injected with highly metastatic Friend leukemia cells. Effects on rstablished metastases. J Exp Med 1991; 173: 313–22.
Iligo M, Sakurai M, Tamura T, Saijo N, Hoshi A. In vivo antitumor activity of multiple injections of recombinant interleukin-2, alone and in combination with three different types of recombinant interferon, on various syngenic murine tumors. Cancer Res 1988; 48: 260–4.
McIntosh JK, Mulè JJ, Krosnick JA. Rosenberg SA. Combination cytokine immunotherapy with tumor necrosis factor a, interleukin 2, and a-interferon and its synergistic antitumor effects in mice. Cancer Res 1989; 49: 1408–14.
Thurman GB, Seals C, Low TLK, and Goldstein AL. Restorative effects of thymosin polypeptides on purified protein derivative-dependent migration inhibition factor production by peripheral blood lymphocytes of adult thymectomized guinea pigs. J. Biol. Resp. Mod. 1984; 3: 160.
Ohta Y, Sueki K, Kitta K, Takemoto K, Ishitsuk H, and Yagi Y. Comparative studies on the immunosuppressive effect among 5-deoxy-5-fluorouridine, ftorafur, and 5-fluorouracil. Gann. 1980; 71: 190.
Ohta Y, Tezuka E, Tamura S, and Yagi Y. Thymosin alpha 1 exerts protective effect against the 5- FU induced bone-marrow toxicity. Int. J. Immunopharmac. 1985; 7: 761.
Ohta Y, Tezuka E, Tamura S, and Yagi Y., N. Y. Acad. Med. 1989; 65: 111.
Kouttab NM, Goldstein AL, Lu M, Lu L, Campbell B, and Maizel AL. Production of human B and T cell growth factor is enhanced by thymic hormones. Immunopharmacology 1988; 16: 97.
Haung KY, Kind PD, Jagoda EM, Goldestein AL. Thymosin treatment modulates productions of interferon. J. Int. Res. 1981; 1: 411.
Shoham J, Eshel I, Aboud M, Salzberg S. Thymic hormonal activity on human peripheral blood lymphocytes, in vitro. II. Enhancement of the production of immune interferon by activated cells. J. Immunol. 1980; 125: 54.
Svedersky LP, Hui A, May L, McKay P, and Stebbing N. Induction and augmentation of mitogen-induced immune interferon production in human peripheral blood lymphocytes by a-desacetyl thymosin al. Eur. J. Immunol. 1982; 12: 244.
Sztein MB, Serrate SA. Characterization of the immunoregulatory properties of thymosin al on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes. Int J. Immunopharmac. 1989; 11: 789.
Sztein MB, Serrate SA, and Goldstein AL. Modulation of interleukin 2 receptor expression on normal human lymphocytes thymic hormones. Proc. Natl. Acad. Sci. USA 1986; 83: 6107.
Leichtling KD, Serrate SA, Sztein MB. Thymosin alpha 1 modulates the expression of high affinity interleukin 2 receptors on normal human lymphocytes. Int. J. Immunopharmac. 1990; 12: 19–29.
Sztein MB, Serrate SA. Characterization of the immunoregulatory properties of thymosin al on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes. Int J. Immunopharmac. 1989; 11: 789–80.
Mule’ JJ, Shu S, Rosenberg SA. The anti tumor efficacy of lymphokine-activated killer cells and recombinant interleukin- 2 in vivo. J. Immunol. 1985; 135: 646–652.
Mastino A, Favalli C, Grelli S, Innocenti F, Garaci E. Thymosin a 1 potentiates interleukin 2-induced cytotoxic activity in mice. Cell. Immunol. 1991; 133: 196–205.
Favalli C, Jezzi T, Mastino A, Rinaldi-Garaci C, Riccardi C, and Garaci E. Modulation of natural killer activity by thymosin alpha 1 and interferon. Cancer Immunol. Immunother. 1985; 20: 189–192.
Mastino A, Favalli C, Grelli S, Rasi G, Pica F, Goldstein AL, Garaci E. Combination therapy with thymosin al potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice. Int.J.Cancer 1992; 50: 1–7.
Leichtling KD, Serrate SA, and Sztein MB. Thymosin alpha 1 modulates the expression of high affinity interleukin 2 receptors on normal human lymphocytes. Int. J. Immunopharmac. 1990; 12: 19.
Serrate SA, Schulof RS, Leondaridis L, Goldstein AL, and Sztein M. Modulation of human natural killer cell cytotoxic activity: limphokine production, and interleukin 2 receptor expression by thymic hormones. J. Immunol. 1987; 139: 2338.
Favalli C, Jezzi T, Mastino A, Rinaldi-Garaci C, Riccardi C, and Garaci E. Modulation of natural killer activity by thymosin alpha 1 and interferon. Cancer Immunol. Immunother. 1985; 20: 189.
Favalli C, Mastino A, Jezzi T, Grelli S, Goldstein AL, and Garaci E. Synergistic effect of thymosin al and alpha-beta Interferon on NK activity in tumor-bearing mice. Int. J. Immunopharmac. 1989; 11: 443.
Bistoni F, Marconi P, Frati L, Bonmassar E, Garaci E. Increase of mouse resistance to Candida Albicans infection by thymosin alpha 1. Infect. Immun. 1982; 36: 609–614.
Fujiki T, Tanaka A. Antibacterial activity of recombinant murine beta interferon Infect. Immun. 1988; 56: 548–551.
Jeevan A, Asherson GL. Recombinant interleukin-2 limits the replication of mycobacterium lepraemurinum and mycobacterium bovis B CG in mice. Infect. Immun. 1988; 56: 660–664.
Phinching AJ. HIV/AIDS pathogenesis and treatment: new twists and turns. Cur. Opin. Immunol. 1991; 3: 537–542.
Garaci E, Mastino A, and Favalli C. Enhanced immune response and antitumor immunity with combinations of biological response modifiers. Bull.
Belardelli F, Gresser I, Maury C, Duvillard D, Prade M, Maunoury MT. antitumor effects of interferon in mice injected with interferon-sensitive and inteferon-resistant Friend Leukemia cella. III Inhibition of growth and necrosis of tumor implanted subcoutaneously. Int J Cancer 1983; 31: 649–653.
Gresser I, Maury C, Wooddrow D, et al. Interferon treatment markedly inhibits the development of tumor metastases in the liver and spleen and increases survival time of mice after intravenous inoculation of Friend erythroleukemia cells. Int J. Cancer 1988; 41: 135–142.
Grasser I, Maury C, Carnaud C, De Maeyer E, Maunoury MT, Belardelli F. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend erythroleukemia cells. VIII. Role of the immune system in the inhibition of visceral metastases. Int J. Cancer 1990; 46: 468474.
Gresser I, Carnaud C, Maury C. et al. Host humoral and cellular mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon αß treatment in mice. J. Exp. Med. 1991; 173: 1193–1203.
Belardelli F, Ciolli V, Testa U, et al. Antitumor effects of interleukin-2 and interleukin-1 in mice transplantated with different syngeneic tumors. Int. J. Cancer 1989; 44: 1108–16.
Belardelli F, Gabriele L, Proietti E, et al. Sinergistic antitumor effects of combined IL-1/IFNα/ß therapy in mice injected with metastatic Friend erythroleukemia cells. Int. J. Cancer 1991; 49: 274–278.
Belardelli F, Ferrantini M, Maury C, Santurbano L, Gresser I. On the biologic and biochemical differences between in vitro and in vivo passaged Friend erythroleukemia cells. Tumorigenicity and capacity to metastaside. Int. J. Cancer 1984; 34: 389–395.
Garaci E, Pica F, Mastino A, Palamara AT, Belardelli F, Favalli C. Antitumor effect of thymosyn α1/Interleukin-2 or thymosyn α1/Interferona/ß following cyclophosphamide in mice injected with highly metastatic friend erythroleukemia cells. J Immunother. 1993; 13: 7–17.
Garaci E and Favalli C. Combination therapy with thymic hormones and cytokines after chemotherapy in cancer treatment. Combination Therapies, Ed. by A.L. Goldstein and E. Garaci, N. York, 1992.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Garaci, E., Mastino, A., Pica, F., Favalli, C. (1993). Combination Therapy with Thymosin α1 and Cytokines in the Treatment of Cancer and Infectious Diseases. In: Garaci, E., Goldstein, A.L. (eds) Combination Therapies 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2964-4_6
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2964-4_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6289-0
Online ISBN: 978-1-4615-2964-4
eBook Packages: Springer Book Archive